Pricing Log in Create free account

Foghorn Therapeutics Inc. (FHTX) vs Humacyte, Inc. (HUMA)

Foghorn Therapeutics Inc. and Humacyte, Inc. are both Biotechnology companies. Foghorn Therapeutics Inc. and Humacyte, Inc. are of similar size ($113.1M and $109.9M). Humacyte, Inc. grew revenue faster over the last twelve months: 149.8% against 52.0%. Foghorn Therapeutics Inc. has the higher net margin (−175.8% vs −4,448.9%) and the higher return on invested capital (0.00% vs −433.7%). Across the 16 metrics below, Foghorn Therapeutics Inc. leads on 12 and Humacyte, Inc. on 4.

Valuation

Metric FHTX HUMA Biotechnology median
P/E n/m n/m 10.60
P/S 3.60 48.58 9.40
P/B n/m 3.30 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.22 n/m 0.66
EV/Sales (0.42) 41.40 9.02
Earnings yield (52.41%) (111.36%) (32.88%)
Free cash flow yield (63.84%) (94.68%) (23.13%)

Profitability

Metric FHTX HUMA Biotechnology median
Gross margin 100.00% (494.58%) 68.51%
Operating margin (198.04%) (5,240.78%) 0.00%
Net margin (175.78%) (4,448.89%) 0.00%
Free cash flow margin (229.49%) (4,599.72%) 0.00%
Return on equity 81.90% (534.42%) (51.96%)
Return on assets (30.06%) (68.16%) (46.06%)
Return on invested capital 0.00% (433.66%) 0.00%

Growth

Metric FHTX HUMA Biotechnology median
Revenue growth (TTM) 51.98% 149.82% 6.76%
EPS growth (last fiscal year) 25.32% 79.37% 29.88%
Revenue growth, 5-year CAGR 135.14% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric FHTX HUMA Biotechnology median
Debt to equity 0.00 2.07 0.00
Current ratio 3.36 6.21 4.97
Net debt to EBITDA 1.88 (0.12) 1.01

Dividend

Metric FHTX HUMA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric FHTX HUMA Biotechnology median
Market cap 113.13m 109.87m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack